|
[1] Wu J, Huang W, He Z. Dendrimers as carriers for siRNA delivery and gene silencing: a review. Scientific World Journal, 2013(2013):630 654.
[2] Snøve O Jr, Rossi J J. Expressing short hairpin RNAs in vivo. Nat Methods, 2006, 3(9):689-695.
[3] Czauderna F, Fechtner M, Dames S,et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res, 2003, 31(11):2705-2716.
[4] Ge Q, Ilves H, Dallas A, et al. Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA, 2010, 16(1):106-117.
[5] Seo M, Lee S, Kim J H, et al. RNAi-based functional selection identifies novel cell migration determinants dependent on PI3K and AKT pathways. Nat Commun, 2014,5:5217.
[6] Abe N, Abe H, Ito Y. Dumbbell-shaped nanocircular RNAs for RNA interference. J Am Chem Soc, 2007, 129(49):15108-15109.
[7] Sørensen D R, Sioud M. Systemic delivery of synthetic siRNAs. Methods Mol Biol, 2010, 629:87-91.
[8] Kaiser P K, Symons R C, Shah SM, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol, 2010, 150(1):33-39.
[9] Heidel J D, Yu Z, Liu J Y, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci U S A, 2007, 104(14):5715-5721.
[10] Leachman S A, Hickerson R P, Schwartz M E, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 2010, 18(2):442-446.
[11] Burnett J C, Rossi J J, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J, 2011, 6(9):1130-1146.
[12] Zimmermann T S, Lee A C, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature, 2006, 441(7089):111-114.
[13] Davis M E, Zuckerman J E, Choi C H, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010, 464(7291):1067-1070.
[14] Efferth T, Koch E. Complex interactions between phytochemicals. the multi-target therapeutic concept of phytotherapy. Curr Drug Targets, 2011, 12(1):122-132.
[15] Lahoute C, Herbin O, Mallat Z, et al. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol, 2011, 8(6):348-358.
[16] Lu J J, Pan W, Hu Y J, et al. Multi-target drugs: the trend of drug research and development. PLoS One, 2012, 7(6):e40262.
[17] Maes M, Fiar Z, Medina M, et al. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 2012, 20(3):127-150.
[18] Flight M H. Neurodegenerative diseases: new kinase targets for Alzheimer's disease. Nat Rev Drug Discov, 2013, 12(10):739.
[19] Ji J, Wernli M, Klimkait T, et al. Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Lett, 2003, 552(2-3):247-252.
[20] Menendez J A, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A, 2004, 101(29):10715-10720.
[21] Tai W, Qin B, Cheng K. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol Pharm, 2010, 7(2):543-556.
[22] 汤禾静, 唐照勇, 刘隆兴,等. siRNA联合沉默MMP9和FAK基因对小鼠黑色素瘤高转移细胞B16F10体外侵袭和迁移的影响. 中国生物工程杂志, 2014, 34(9):40-47. Tang H J, Tang Z Y, Liu L X, et al. Effect of siRNA combined silencing MMP-9 and FAK on invasion and migration of mouse melanoma highly metastatic cells B16F10 in vitro. China Biotechnology, 2014, 34(9):40-47.
[23] Anderson J, Banerjea A, Akkina R. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides, 2003, 13(5):303-312.
[24] Gondi C S, Lakka S S, Dinh D H, et al. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene, 2004, 23(52):8486-8496.
[25] Kargiotis O, Chetty C, Gogineni V, et al. uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol, 2008, 33(5):937-947.
[26] Kunigal S, Lakka S S, Gondi C S, et al. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer, 2007, 121(10):2307-2316.
[27] Rice R R, Muirhead A N, Harrison B T, et al. Simple, robust strategies for generating DNA-directed RNA interference constructs. Methods Enzymol, 2005, 392:405-419.
[28] Akashi H, Miyagishi M, Yokota T, et al. Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol Biosyst, 2005, 1(5-6):382-390.
[29] Liu Y P, Haasnoot J, Berkhout B. Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res, 2007, 35(17):5683-5693.
[30] Sano M, Li H, Nakanishi M, et al. Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol Ther, 2008, 16(1):170-177.
[31] Lee S H, Mok H, Jo S, et al. Dual gene targeted multimeric siRNA for combinatorial gene silencing. Biomaterials, 2011, 32(9):2359-2368.
[32] Frieden M, Aviñó A, Tarrasón G, et al. Synthesis of oligonucleotide-peptide conjugates carrying the c-myc peptide epitope as recognition system. Chem Biodivers, 2004, 1(6):930-938.
[33] Aviñó A, Ocampo S M, Perales J C, et al. Branched RNA: a new architecture for RNA interference. J Nucleic Acids, 2011, 2011(2011),ID586935.
[34] Chang C I, Lee T Y, Kim S, et al. Enhanced intracellular delivery and multi-target gene silencing triggered by tripodal RNA structures. J Gene Med. 2012, 14(2):138-146.
[35] Nakashima Y, Abe H, Abe N, et al. Branched RNA nanostructures for RNA interference. Chem Commun (Camb), 2011, 47(29):8367-8369.
[36] Shin D, Lee H, Kim S I, et al. Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. RNA, 2009, 15(5):898-910.
[37] Suhy D A, Kao S C, Mao T, et al. Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther, 2012, 20(9):1737-1749.
[38] Chang C I, Kang H S, Ban C, et al. Dual-target gene silencing by using long, synthetic siRNA duplexes without triggering antiviral responses. Mol Cells, 2009, 27(6):689-695.
[39] Wu Y Y, Chen L, Wang G L, et al. Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF. J Mol Histol, 2013, 44(4):433-445.
[40] Peng W, Chen J, Qin Y, et al. Long double-stranded multiplex siRNAs for dual genes silencing. Nucleic Acid Ther, 2013, 23(4):281-288.
[41] Chang C I, Lee T Y, Yoo J W, et al. Branched, tripartite-interfering RNAs silence multiple target genes with long guide strands. Nucleic Acid Ther, 2012, 22(1):30-39.
[42] 蒋婷婷, 温晓霞, 陈尧. 沉默 c2orf68 基因对结直肠癌细胞增殖的影响. 中国生物工程杂志, 2014, 34(2):7-13. Jiang T T, Weng X X, Chen Y. Effect of silencing c2orf68 gene on the proliferation of colorectal adenocarcinoma cells. China Biotechnology, 2014, 34(2):7-13.
[43] 王鑫, 陈玲, 陆航,等. RNAi沉默CXCR7对人结肠癌细胞 SW620特异性靶向抑制的实验研究.中国生物工程杂志, 2014, 34(2):14-20. Wang X, Chen L, Lu H, et al. Experimental study of specific targeted inhibition from RNAi silencing CXCR7 to human colon cancer cell SW620. China Biotechnology, 2014, 34(2):14-20.
[44] Qin J, Xu Y, Li X, et al. Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on the hepatocarcinoma cell. Exp Mol Pathol, 2014, 96(1):1-8.
|
